Jun. 21, 2017

Novopyxis – The first start-up identified by LEO Science & Tech Hub

LEO Pharma announces an investment in the biotechnology company Novopyxis to support the development of an early-stage drug delivery device designed to increase the penetration of topical treatments in the skin.

The hand-held aerosol device will be clinically tested on people with alopecia, where there is a high need for alternative treatment options to painful steroid injections. Alopecia is an autoimmune disease leading to hair loss from all or some parts of the body, usually the scalp.

Read the press release

News from the hub

Sep. 2018 18 LEO Science & Tech Hub Partners with Epicore Biosystems to Explore Wearable Skin Sensors to Improve Dermatologic Treatment Regimens

LEO Science & Tech Hub, the Boston-based R&D innovation unit of LEO Pharma, has announced a new partnership with Epicore Biosystems focused on exploring the use of a non-invasive, wearable sweat sensor to measure prognostic biomarkers in real time, monitor patient response and inform treatment decisions. The initial project will include a proof of concept study in […]

Read more
Jul. 2018 11 Hacking Dermatology Selects 5 Finalist Teams for Incubation

Hacking Dermatology is an initiative that aims to bring interdisciplinary teams together to solve the important challenges facing patients with skin disease. It is led and supported by a consortium of academic, non-profit, and industry partners, including Hacking Medicine Institute (HMi), LEO Pharma, Advancing Innovation in Dermatology (AID), MIT Hacking Medicine, and the Lahey Medical […]

Read more